Anderson G, Koup J, Slaughter R, Edwards W D, Resman B, Hook E
Ther Drug Monit. 1981;3(4):325-32. doi: 10.1097/00007691-198104000-00002.
The Koup et al. and Chiou et al. clearance estimation methods were evaluated n 19 chronic obstructive pulmonary disease (COPD)/asthmatic patients who were receiving aminophylline by continuous infusion. Estimated theophylline clearance (Clest) was determined using two serum concentrations obtained during the first few hours of therapy (1-16 hr) prior to achievement of steady state. Actual theophylline clearance (Clact) was determined after steady state conditions had been achieved (defined as 4-5 half-lives at the same infusion rate). The correlation between Clact and Clest was highly significant for both the Koup et al. and Chiou et al. methods, r = 0.865, p less than 0.001, and r = 0.858, p less than 0.001, respectively. The clearance estimation methods were compared with the Food and Drug Administration (FDA) dosage guidelines and shown to be clearly superior in predicting therapeutic steady state theophylline concentrations.
在19名接受氨茶碱持续输注的慢性阻塞性肺疾病（COPD）/哮喘患者中，对库普等人和邱等人的清除率估算方法进行了评估。使用在达到稳态之前治疗的最初几个小时（1至16小时）内获得的两种血清浓度来确定估算的茶碱清除率（Clest）。在达到稳态条件后（定义为以相同输注速率的4至5个半衰期）确定实际的茶碱清除率（Clact）。对于库普等人和邱等人的方法，Clact与Clest之间的相关性都非常显著，分别为r = 0.865，p小于0.001和r = 0.858，p小于0.001。将清除率估算方法与美国食品药品监督管理局（FDA）的剂量指南进行了比较，结果表明在预测治疗性稳态茶碱浓度方面明显更优。
